Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative
Asad E Patanwala,Xuya Xiao,Thomas E Hills,Alisa M Higgins,Colin J McArthur,G Caleb Alexander,Hemalkumar B Mehta,National Covid Cohort Collaborative (N3C) Consortium,Adam B Wilcox,Adam M Lee,Alexis Graves,Alfred Jerrod Anzalone,Amin Manna,Amit Saha,Amy Olex,Andrea Zhou,Andrew E Williams,Andrew Southerland,Andrew T Girvin,Anita Walden,Anjali A Sharathkumar,Benjamin Amor,Benjamin Bates,Brian Hendricks,Brijesh Patel,Carolyn Bramante,Cavin Ward-Caviness,Charisse Madlock-Brown,Christine Suver,Christopher Chute,Christopher Dillon,Chunlei Wu,Clare Schmitt,Cliff Takemoto,Dan Housman,Davera Gabriel,David A Eichmann,Diego Mazzotti,Don Brown,Eilis Boudreau,Elaine Hill,Elizabeth Zampino,Emily Carlson Marti,Emily R Pfaff,Evan French,Farrukh M Koraishy,Federico Mariona,Fred Prior,George Sokos,Greg Martin,Harold Lehmann,Heidi Spratt,Hongfang Liu,Hythem Sidky,J W Awori Hayanga,Jami Pincavitch,Jaylyn Clark,Jeremy Richard Harper,Jessica Islam,Jin Ge,Joel Gagnier,Joel H Saltz,Joel Saltz,Johanna Loomba,John Buse,Jomol Mathew,Joni L Rutter,Julie A McMurry,Justin Guinney,Justin Starren,Karen Crowley,Katie Rebecca Bradwell,Kellie M Walters,Ken Wilkins,Kenneth R Gersing,Kenrick Dwain Cato,Kimberly Murray,Kristin Kostka,Lavance Northington,Lee Allan Pyles,Leonie Misquitta,Lesley Cottrell,Lili Portilla,Mariam Deacy,Mark M Bissell,Marshall Clark,Mary Emmett,Mary Morrison Saltz,Matvey B Palchuk,Melissa A Haendel,Meredith Adams,Meredith Temple-O'Connor,Michael G Kurilla,Michele Morris,Nabeel Qureshi,Nasia Safdar,Nicole Garbarini,Noha Sharafeldin,Ofer Sadan,Patricia A Francis,Penny Wung Burgoon,Peter Robinson,Philip R O Payne,Rafael Fuentes,Randeep Jawa,Rebecca Erwin-Cohen,Rena Patel,Richard A Moffitt,Richard L Zhu,Rishi Kamaleswaran,Robert Hurley,Robert T Miller,Saiju Pyarajan,Sam G Michael,Samuel Bozzette,Sandeep Mallipattu,Satyanarayana Vedula,Scott Chapman,Shawn T O'Neil,Soko Setoguchi,Stephanie S Hong,Steve Johnson,Tellen D Bennett,Tiffany Callahan,Umit Topaloglu,Usman Sheikh,Valery Gordon,Vignesh Subbian,Warren A Kibbe,Wenndy Hernandez,Will Beasley,Will Cooper,William Hillegass,Xiaohan Tanner Zhang
DOI: https://doi.org/10.1097/CCM.0000000000006444
2024-10-04
Abstract:Objectives: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19. Design: Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach. Setting: The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals. Patients: Adults who were hospitalized for COVID-19. Interventions: Newly initiated on baricitinib or tocilizumab. Measurements and main results: Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0 ± 15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85-0.98) and hospital (OR, 0.88; 95% CI, 0.82-0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90-0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75-0.99), although no difference in ICU length of stay was noted between the two groups. Conclusions: In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.